Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate Immunogenicity and Safety of Boostrix When co-Administered With Fluarix in Subjects 19 Years of Age and Older.

Next Previous
Trial Profile

A Study to Evaluate Immunogenicity and Safety of Boostrix When co-Administered With Fluarix in Subjects 19 Years of Age and Older.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary) ; Influenza virus vaccine (Primary)
  • Indications Diphtheria; Influenza virus infections; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline

Most Recent Events

  • 03 Feb 2012 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
  • 03 Feb 2012 Actual patient number is 1726 according to ClinicalTrials.gov.
  • 30 Dec 2011 Results for the exploratory cohort of subjects aged 65 years or older published in Vaccine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top